Genentech, Inc.

Diego Ellerman

Christoph Spiess

Teemu T Junttila

Paul J Carter

Isidro Hotzel

Ji Li

Danielle Dicara

Justin M Scheer

Twyla Noelle Lombana

Dionysos Slaga

Justin Scheer

The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.

Bispecific antigen-binding molecules and methods of use

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

Humanized and affinity matured antibodies to FcRH5 and methods of use

Growing community of inventors

San Francisco, CA, United States of America

Diego Ellerman